Dr. Orme Stephen

Dr. Orme Stephen

Consultant Endocrinologist/Honorary Senior Lecturer

Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom

plus Speciality




1. 1984: MB ChB Manchester
2. 1988: MRCP (UK)
3. 1996: AMISM
4. 1997: MD Manchester
5. 1999: FRCPEdin
6. 2000: FRCPLond

Academic positions:

Present Appointment

November 1997- Present: Consultant Endocrinologist/Honorary Senior Lecturer at  Leeds Teaching Hospitals NHS Trust


I have been a Consultant Endocrinologist, working in Leeds Teaching Hospitals since November 1997.
I am responsible for delivering a significant proportion of the tertiary endocrine service (including pituitary disease and metabolic bone disease) for Leeds and the wider area.

Recent Patient Satisfaction Survey from my Bone Clinic (March 2012) showed 98% patient satisfaction with our service.

In addition I have 10 General Medical In-Patient and contribute to the Acute Medical Rota by weekend and evening work on the Acute Medical Ward.


Programme Committee member SFE (2008-present) & Clinical Coordinator for BES Meeting Birmingham, April 2011. Developing symposia & arranging speakers for annual 4 day international meeting, Marking abstracts, planning oral sessions, judging oral presentations & chairing sessions.

Member of SFE Public Engagement Committee (2009-2012) as one of 3 web editors, developed public website ,'You & Your Hormones'.  Launched at  BES meeting (April 2011). Involved commissioning over 150 articles, writing, reviewing & editing work. Website had >80,000 visits in 12 months .

SFE representative to RCP for professional CPD (Feb 2010-present), approving a large number of applications for training /scientific meetings.

Educational supervisor for FY1, FY2, ST1 & SpR.  Representative on Diabetes & Endocrinology STC.

RCP PACES Examiner & Co-Host  (Leeds July 09 & 10 ) wrote 3 scenarios for station 5, adopted by RCP.

Invited lectures (2011-12): Final year revision lecture (Leeds Medical School) FY1's, Endocrine Emergencies (LGI), International Bone Meeting (London), SpR Training Meeting (Tadcaster) , Osteoporosis Nurses Meeting (Sheffield), National Geriatric Meeting (Wakefield), National Osteoporosis Society Meeting (Leeds), Yorkshire Regional RCP meeting (Leeds) &  St Bartholemew's Hospital (London). Good feedback from all events.

Research interests:

My main research interest, and the subject of my MD thesis, is a large retrospective epidemiological study of cancer incidence and all cause mortality in acromegaly.   In a parallel study working with Prof. Timothy Bishop at the Imperial Cancer Research Centre, St. James’s Hospital,  I have studied the families of patients with acromegaly in West Yorkshire to determine the local incidence of familial (non - MEN 1) acromegaly and to investigate the occurrence of cancer in the families of patients with acromegaly. I have continued to do collaborative research with Professor Marta Korbonits(St Bartholomew’s Hospital London) into familial acromegaly (FIPA) leading to a publication in the New England Journal of Medicine (2011).   

I have also been responsible for a number of studies involving growth hormone (GH) replacement therapy in GH deficient adults, in collaboration with The Centre for Bone and Body Composition (Medical Physics, LGI), Department of Psychology St. James's Hospital, Department of Medicine (LGI), and The Centre for Non-Linear Studies and Computational Biology Group, Department of Physiology, University of Leeds.   

I have an interest in osteoporosis research having evaluated the effect of disodium etidronate (Didronel) and high dose calcium in a clinical study of osteoporotics and investigated the relationship between skin thickness and bone mass in postmenopausal women with osteoporosis and normal controls.  

In collaboration with Professor Arun Holden (Department of Physiology, University of Leeds) I developed research projects for and supervised 2 PhD students (Dr F Homayoun Valiani and Dr A Al-Hazimi).

I have been principal local investigator in 2 Pharmaceutical Company Sponsored multi-centre studies (Teriparatide [synthetic PTH] in the treatment of osteoporosis, Pegvisomant [GH receptor blocker] in the treatment of acromegaly.

With Professor Bun Tan I have supervised an SpR (Dr Rob Moisey)  in a study of the relationship between measures of cardiac power and cardiac function and a disease specific patient well-being questionnaire (AGHDA score).

With Associate Professor Ramzi Ajjan I have studied the effects of thyroid diseases on cardiac risk parameters, including clot structure function.

I am presently principal investigator (with Dr Richard McNally – University of Newcastle) in a study of second tumours in patients with acromegaly who have undergone radiotherapy and local principal investigator in the PAGMA study (Society for Endocrinology sponsored study of Post-Radiation Management of Patients with Graves’ Disease)

I am a referee, for Clinical Endocrinology and The Journal of Clinical Endocrinology and Metabolism. I have been a regular attender and contributor to the National Osteoporosis Society, the Pituitary Society, the Society of Endocrinology and the Endocrine Society.

I am Regional Liaison Officer for the Society for Endocrinology, Programme Committee Member for the British Endocrine Society and, Principal Investigator Steering Committee
Member UK Acromegaly Database.

Any other information:


1. Orme SM, Lamb JT, Nelson M, & Belchetz PE. (1991)   Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide.  Postgraduate Medical Journal; 67: 466-468.
2. Orme SM, & Belchetz PE. (1991) Isolated ACTH deficiency. Clinical Endocrinology; 35: 213-217.
3. Orme SM, Sebastian JP, Oldroyd B, Stewart SP, Grant PJ, Stickland MH, Smith MA, & Belchetz PEB. (1992) Comparison of measures of body composition in a trial of low dose growth hormone replacement therapy.  Clinical Endocrinology; 37: 453-459.
4. Orme SM, Lamb JT, Nelson M, & Belchetz PE. (1992) Shrinkage of thyrotrophin secreting pituitary adenoma treated with Octreotide.  Year Book of Endocrinology; 27-29.
5. Orme SM, Sebastian JP, Page MD, Cowan C, & Belchetz PE. (1993)  Thyrotoxicosis increases right to left shunt in congenital cyanotic heart disease.  Clinical Endocrinology; 39: 253-256.
6. Orme SM.(1993)  Heart disease in acromegaly: a role for Octreotide? ASAP Newsletter ;20: 1-2.
7. Padayatty SJ, Orme SM, Zenobi PD, Stickland MH, Belchetz PE & Grant PJ. (1993)  The effects of Insulin-like Growth Factor-1 on Plasminogen Activator Inhibitor 1 synthesis and secretion: results from in-vitro and in-vivo studies.  Thrombosis and Haemostasis ;70(6): 1009-1013.
8. Orme SM, Simpson M, Stewart SP, Oldroyd B, Westmacott CF, Smith MA, Belchetz PE. (1994) Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation. Clinical Endocrinology; 41: 245-250.
9. Orme SM, & Belchetz PE. (1994)  Is a low skinfold thickness an indicator of osteoporosis?  Clinical  Endocrinology ; 41: 283-287.
10. Nelson M, Lamb JT, Sebastian JP, Orme SM & Belchetz PE.(1995) Sequential petrosal sinus sampling - a simplified technique for the diagnosis of Cushing's disease. Neuroradiology ; 37 suppl:361-362.
11. Orme SM & Belchetz PE.(1995) Is a low skinfold thickness an indicator of osteoporosis?  Menopause Digest ; 3: 29-30.
12. Orme SM, Peacey SR, Barth JH, & Belchetz PE.(1996) Comparison of plasma cortisol responses to insulin induced hypoglycaemia (IIH), IM glucagon stimulation test (IMGST) and short synacthen test (SST).  Clinical Endocrinology ; 45: 135-140.
13. Peace KA, Orme SM, Thompson AR, Padayatty SJ, Ellis AW, & Belchetz PE. (1997)  Cognitive dysfunction in patients treated for pituitary tumours. Journal of Clinical and Experimental  Neuropsychology ;19: 1-6.
14. Peace KA, Orme SM, Sebastian JP, Thompson AR, Barnes S, Ellis A,   & Belchetz PE. (1997) Self-reporting of mood and social adjustment in adult patients with pituitary disease. Clinical Endocrinology; 46: 445-450.  
15. Sönksen PH, Jacobs HS, Orme SM & Belchetz PE.(1997)  Acromegaly and colonic cancer. Clinical Endocrinology, 47, 647-648.
16. Padayatty SJ, Orme SM, Nelson M, Lamb JT, & Belchetz PE. (1998) Bilateral sequential inferior petrosal sinus sampling with corticotrophin releasing hormone stimulation in the diagnosis of Cushing's disease. European Journal of Endocrinology, 139, 161-166.
17. Orme SM, McNally R, Cartwright RA, & Belchetz PE. (1998) Mortality and cancer incidence in acromegaly; a retrospective cohort study. Journal of Clinical Endocrinology and Metabolism, 83, 2730-2734.
18. Peace KA, Orme SM, Padayatty JS, Godfrey HPD, & Belchetz PE. (1998)  Cognitive dysfunction in patients with pituitary tumour who have been treated with transfrontal or  transsphenoidal surgery and radiotherapy. Clinical Endocrinology, 49, 391-396.
19. Orme SM, Price A, Weetman AP & Ross RJM.(1998) Comparison of the diagnostic utility of the simplified and standard im glucagon stimulation test (IMGST). Clinical Endocrinology, 49, 773-778.
20. Orme SM. (1999) Epidemiology, cancer incidence and mortality in acromegaly.  CME Endocrinology & Diabetes, 2,40-43.
21. Orme SM. (2001) TSH too high? CME Endocrinology & Diabetes,3, 75-78.
22. Rajeswaran C, Bodansky HJ & Orme SM. (2005) Resolution of Insulin treated diabetes and hypertension following resection of an asymptomatic phaeochromocytoma. Practical Diabetes International, 22, 313-315.
23. Rajeswaran C, Barth J, Spencer J  & Orme SM. (2007) Utility of Biochemical Screening in the context of evaluating patients with a presumptive diagnosis of osteoporosis. Clinical Rheumatology, 26: 362-365.
24. Moisey RS, McPherson S, Wright M and Orme SM. (2007) Thyroiditis and iodine mumps following angioplasty. Nephrology Dialysis Transplantation, 22/4, 1250-1252.
25. Moisey R, Swinburne J and Orme S. (2008) Serum Testosterone and calculated bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecoanate. Clinical Endocrinology , 69, 642-647.
26. Rathi MS, Ajjan R and Orme SM. (2008) A case of parathyroid carcinoma with severe hungry bone syndrome and review of literature. Exp Clin Endocrinol Diabetes, 116, 489-490.
27. Moisey R, Orme S, Barker D, Lewis N, Sharp L, Clements RE, Goldspink DF and Tan LB (2009) Cardiac functional reserve is diminished in growth hormone deficient adults. CV therapeutics,27, 34-41
28. Moisey R, Barker D, Lewis N, Sharp L, Clements RE, Goldspink DF, Tan LB, Orme SM (2009) Reduced cardiac functional reserve and quality of life in adults with GH deficiency. Clin Endocrinol, 71, 543-548.
29. Harvinder S, Stals K, Unterlander D, Balding DJ, Thomas MG, Kumar AV, Besser GM, Atkinson AB. Morrison PJ, Howlett TA, Levy MJ, Orme SM et al. (2011) AIP Mutation in Pituitary Adenomas in the 18th Century and Today. N Engl J Med , 364, 43-50.
30. Charopoulos I, Orme S, Giannoudis PV (2011) Fracture risk associated with chronic use of bisphosphonates: evidence today.Expert Opin Drug Saf. 10, 67-76.
31. Charopoulos I, Orme S,  and Giannoudis PV (2011) The role and efficacy of denosumab in osteoporosis: an update. Expert Opin Drug Saf,10, 205-17.
32. Hooper IMW, Stuijver JF, Orme SM et al., (2012) Thyroid dysfunction and fibrin network structure: A mechanism for increased thrombotic risk in hyperthyroid individuals. J Clin Endocrinol Metab, 97, 1463-73.
33. Stuijver, DJ, Hooper JMW, Orme SM et al., Fibrin clot structure and fibrinolysis in hypothyroid individuals: the effects of normalising thyroid hormone levels. J Thromb Haemost. 2012 Aug;10(8):1708-10.

What I think of the idea behind WebmedCentral and WebmedCentral plus: